EP4613337A2 — Crystalline form of triethylenetetramine tetrahydrochloride and its pharmaceutical uses
Assigned to Orphalan SA · Expires 2025-09-10 · 1y expired
What this patent protects
The present invention describes a new crystalline form of triethylenetetramine tetrachloride which has improved room temperature stability over known forms and over the dichloride salt. The new crystalline form is characterised by having peaks in an XRPD spectrum at 22.9, 25.4, 2…
USPTO Abstract
The present invention describes a new crystalline form of triethylenetetramine tetrachloride which has improved room temperature stability over known forms and over the dichloride salt. The new crystalline form is characterised by having peaks in an XRPD spectrum at 22.9, 25.4, 25.8, 26.6, 34.6 and 35.3 ± 0.1°2θ and Raman shifts 943, 1173, 1527 and 1612 ± 5 cm<sup>-1</sup>. The crystalline form of triethylenetetramine tetrachloride is useful in the treatment of Wilson's disease.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.